Tumour heterogeneity and drug resistance: Personalising cancer medicine through functional genomics

Biochemical Pharmacology

Volumn 83, Issue 8, 2012, Pages 1013-1020

  Lee, Alvin J X ^a   Swanton, Charles ^a,b  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Biomarkers; Cancer; Chromosomal instability; Drug resistance; RNA interference

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CHLORAMBUCIL; CID 1340132; CISPLATIN; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; MELPHALAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIMUSTINE; NSC 154829; OLAPARIB; PACLITAXEL; PROTEIN KINASE B INHIBITOR; R 3200; RETINOIC ACID; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CELL LINE; CHROMOSOMAL INSTABILITY; CHROMOSOME 8Q; CHROMOSOME 8Q22; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TARGETING; FUNCTIONAL GENOMICS; GENE DOSAGE; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; GENE SILENCING; GENE TARGETING; HUMAN; ISOGENIC CELL LINE; NONHUMAN; ONCOGENE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; QUALITY OF LIFE; REVIEW; RNA ANALYSIS; RNA INTERFERENCE; SOLID TUMOR;

CHROMOSOMAL INSTABILITY; DRUG DESIGN; DRUG DISCOVERY; DRUG RESISTANCE, NEOPLASM; GENETIC HETEROGENEITY; GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS; RNA INTERFERENCE;

EID: 84858005794     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2011.12.008     Document Type: Review

References (83)

1. Raguz S, Yague E. Resistance to chemotherapy: new treatments and novel insights into an old problem. Br J Cancer 2008;99:387-91.
2. Rubin BP, Duensing A. Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumors. Lab Invest 2006;86:981-6. (Pubitemid 44423063)
3. Targeted Cancer Therapies.
4. Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010;464:999-1005.
5. Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, Burleigh A, et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009;461:809-13.
6. Gerlinger M, Swanton C. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br J Cancer 2010;103:1139-43.
7. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5:275-84. (Pubitemid 40488633)
8. Downward J. RNA interference-based functional genomics in cancer research - an introduction. Oncogene 2000;23:8334-5. (Pubitemid 39540712)
9. Downward J. RNA interference. BMJ 2004;328:1245-8.
10. Lee AJX, Kolesnick R, Swanton C. RNAi-mediated functional analysis of pathways influencing cancer cell drug resistance. Expert Rev Mol Med 2009;11.
11. Paddison PJ, Caudy AA, Bernstein E, Hannon GJ, Conklin DS. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev 2002;16:948-58. (Pubitemid 34408544)
12. Rao DD, Vorhies JS, Senzer N, Nemunaitis J. siRNA vs shRNA: similarities and differences. Adv Drug Deliv Rev 2009;61:746-59.
13. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 1980;77:1561-5. (Pubitemid 10073801)
14. Blagosklonny MV. Mitotic arrest and cell fate: why and how mitotic inhibition of transcription drives mutually exclusive events. Cell Cycle 2007;6:70-4. (Pubitemid 46178022)
15. Whitehurst AW, Bodemann BO, Cardenas J, Ferguson D, Girard L, Peyton M, et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 2007;446:815-9. (Pubitemid 46582032)
16. Whitehurst AW, Xie Y, Purinton SC, Cappell KM, Swanik JT, Larson B, et al. Tumor antigen acrosin binding protein normalizes mitotic spindle function to promote cancer cell proliferation. Cancer Res 2010;70:7652-61.
17. Swanton C, Marani M, Pardo O, Warne PH, Kelly G, Sahai E, et al. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 2007;11:498-512. (Pubitemid 46856907)
18. Juul N, Szallasi Z, Eklund AC, Li Q, Burrell RA, Gerlinger M, et al. Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. Lancet Oncol 2010;11:358-65.
19. Swanton C, Nicke B, Schuett M, Eklund AC, Ng C, Li Q, et al. Chromosomal instability determines taxane response. Proc Natl Acad Sci USA 2009;106:8671-6.
20. Lee AJ, Roylance R, Sander J, Gorman P, Endesfelder D, Kschischo M, et al. CERT depletion predicts chemotherapy benefit and mediates cytotoxic and polyploid-specific cancer cell death through autophagy induction. J Pathol 2011.
21. Bartz SR, Zhang Z, Burchard J, Imakura M, Martin M, Palmieri A, et al. Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. Mol Cell Biol 2006;26:9377-86. (Pubitemid 44904431)
22. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003;97:2187-95. (Pubitemid 36444059)
23. Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 2004;96:1659-68. (Pubitemid 39585635)
24. Majdak EJ, Debniak J, Milczek T, Cornelisse CJ, Devilee P, Emerich J, et al. Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma. Cancer 2005;104:1004-12. (Pubitemid 41170228)
25. van Haaften G, Romeijn R, Pothof J, Koole W, Mullenders LH, Pastink A, et al. Identification of conserved pathways of DNA-damage response and radiation protection by genome-wide RNAi. Curr Biol 2006;16:1344-50. (Pubitemid 43975370)
26. Giroux V, Iovanna J, Dagorn JC. Probing the human kinome for kinases involved in pancreatic cancer cell survival and gemcitabine resistance. FASEB J 2006;20:1982-91. (Pubitemid 44953898)
27. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 2010;123:725-31.
28. Mullenders J, von der Saal W, van Dongen MMW, Reiff U, van Willigen R, Beijersbergen RL, et al. Candidate biomarkers of response to an experimental cancer drug identified through a large-scale RNA interference genetic screen. Clin Cancer Res 2009;15:5811-9.
29. Morgan-Lappe S, Woods KW, Li Q, Anderson MG, Schurdak ME, Luo Y, et al. RNAi-based screening of the human kinome identifies Akt-cooperating kinases: a new approach to designing efficacious multitargeted kinase inhibitors. Oncogene 2006;25:1340-8. (Pubitemid 43336462)
30. Hattori H, Zhang X, Jia Y, Subramanian KK, Jo H, Loison F, et al. RNAi screen identifies UBE2D3 as a mediator of all-trans retinoic acid-induced cell growth arrest in human acute promyelocytic NB4 cells. Blood 2007;110:640-50. (Pubitemid 47105403)
31. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007;12:395-402. (Pubitemid 47539306)
32. Iorns E, Turner NC, Elliott R, Syed N, Garrone O, Gasco M, et al. Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell 2008;13:91-104. (Pubitemid 351163160)
33. Mendes-Pereira AM, Sims D, Dexter T, Fenwick K, Assiotis I, Kozarewa I, et al. Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen. Proc Natl Acad Sci USA 2011.
34. Turner NC, Lord CJ, Iorns E, Brough R, Swift S, Elliott R, et al. A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J 2008;27:1368-77. (Pubitemid 351655175)
35. Harries M, Smith I. The development and clinical use of trastuzumab (Herceptin). Endocr Relat Cancer 2002;9:75-85. (Pubitemid 34832161)
36. Jordan VC. Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. Br J Pharmacol 2006;147(Suppl 1):S269-76. (Pubitemid 43077285)
37. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;351:1451-67.
38. Legha SS, Buzdar AU, Hortobagyi GN, Wiseman C, Benjamin RS, Blumenschein GR. Tamoxifen. JAMA J Am Med Assoc 1979;242:49-52.
39. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434:913-7. (Pubitemid 40559005)
40. Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF, et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009;137:835-48.
41. Ngo VN, Davis RE, Lamy L, Yu X, Zhao H, Lenz G, et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature 2006;441:106-10.
42. Schlabach MR, Luo J, Solimini NL, Hu G, Xu Q, Li MZ, et al. Cancer proliferation gene discovery through functional genomics. Science 2008;319:620-4. (Pubitemid 351197064)
43. Krastev DB, Slabicki M, Paszkowski-Rogacz M, Hubner NC, Junqueira M, Shevchenko A, et al. A systematic RNAi synthetic interaction screen reveals a link between p53 and snoRNP assembly. Nat Cell Biol 2011;13:809-18.
44. Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer 2009;9:749-58.
45. Bommi-Reddy A, Almeciga I, Sawyer J, Geisen C, Li W, Harlow E, et al. Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen. Proc Natl Acad Sci USA 2008;105:16484-9.
46. Cully M, Downward J. SnapShot: Ras Signaling. Cell 2008;133:1292-e1.
47. Wang Y, Ngo VN, Marani M, Yang Y, Wright G, Staudt LM, et al. Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells. Oncogene 2010;29:4658-70.
48. Vicent S, Chen R, Sayles LC, Lin C, Walker RG, Gillespie AK, et al. Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models. J Clin Invest 2010;120:3940-52.
49. Hohenstein P, Hastie ND. The many facets of the Wilms' tumour gene, WT1. Hum Mol Genet 2006;15:R196-201. (Pubitemid 44446794)
50. Sarthy AV, Morgan-Lappe SE, Zakula D, Vernetti L, Schurdak M, Packer JC, et al. Survivin depletion preferentially reduces the survival of activated K-Ras-transformed cells. Mol Cancer Ther 2007;6:269-76. (Pubitemid 46206691)
51. Ji Z, Mei FC, Lory PL, Gilbertson SR, Chen Y, Cheng X. Chemical genetic screening of KRAS-based synthetic lethal inhibitors for pancreatic cancer. Front Biosci 2009;14:2904-10.
52. Trembath DG, Lal A, Kroll DJ, Oberlies NH, Riggins GJ. A novel small molecule that selectively inhibits glioblastoma cells expressing EGFRvIII. Mol Cancer 2007;6:30.
53. Cancer Genome Project Cambridge. UK: Wellcome Trust Sanger Institute; 2010.
54. Chu EC, Tarnawski AS. PTEN regulatory functions in tumor suppression and cell biology. Med Sci Monit 2004;10:RA235-41. (Pubitemid 39424480)
55. Yoshida K, Miki Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci 2004;95:866-71. (Pubitemid 40045520)
56. Li HF, Keeton A, Vitolo M, Maddox C, Rasmussen L, Hobrath J, et al. A high-throughput screen with isogenic PTEN+/+ and PTEN-/- cells identifies CID1340132 as a novel compound that induces apoptosis in PTEN and PIK3CA mutant human cancer cells. J Biomol Screen 2011;16:383-93.
57. Evers B, Schut E, van der Burg E, Braumuller TM, Egan DA, Holstege H, et al. A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors. Clin Cancer Res 2010;16:99-108.
58. McClean S, Costelloe C, Denny WA, Searcey M, Wakelin LP. Sequence selectivity, cross-linking efficiency and cytotoxicity of DNA-targeted 4-anilinoquinoline aniline mustards. Anticancer Drug Des 1999;14:187-204. (Pubitemid 29428024)
59. Li Y, Zou L, Li Q, Haibe-Kains B, Tian R, Desmedt C, et al. Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med 2010;16:214-8.
60. Roylance R, Endesfelder D, Gorman P, Burrell RA, Sander J, Tomlinson I, et al. Relationship of Extreme Chromosomal Instability with Long-term Survival in a Retrospective Analysis of Primary Breast Cancer. Cancer Epidemiol Biomarkers Prev 2011;20:2183-94.
61. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature 1997;386:623-7. (Pubitemid 27175430)
62. Roschke AV, Tonon G, Gehlhaus KS, McTyre N, Bussey KJ, Lababidi S, et al. Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res 2003;63:8634-47. (Pubitemid 38064038)
63. Duesberg P, Stindl R, Hehlmann R. Explaining the high mutation rates of cancer cells to drug and multidrug resistance by chromosome reassortments that are catalyzed by aneuploidy. Proc Natl Acad Sci USA 2000;97:14295-300. (Pubitemid 32036702)
64. Lee AJX, Endesfelder D, Rowan AJ, Walther A, Birkbak NJ, Futreal PA, et al. Chromosomal Instability Confers Intrinsic Multidrug Resistance. Cancer Res 2011;71:1858-70.
65. Roschke AV, Kirsch IR. Targeting cancer cells by exploiting karyotypic complexity and chromosomal instability. Cell Cycle 2005;4:679-82. (Pubitemid 41353851)
66. Storchova Z, Breneman A, Cande J, Dunn J, Burbank K, O'Toole E, et al. Genomewide genetic analysis of polyploidy in yeast. Nature 2006;443:541-7. (Pubitemid 44527285)
67. Torres EM, Sokolsky T, Tucker CM, Chan LY, Boselli M, Dunham MJ, et al. Effects of aneuploidy on cellular physiology and cell division in haploid yeast. Science 2007;317:916-24. (Pubitemid 47301313)
68. Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi ZA. signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 2006;38:1043-8. (Pubitemid 44325930)
69. Birkbak NJ, Eklund AC, Li Q, McClelland SE, Endesfelder D, Tan P, et al. Paradoxical Relationship between Chromosomal Instability and Survival Outcome in Cancer. Cancer Res 2011;71:3447-52.
70. Walther A, Houlston R, Tomlinson I. Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis. Gut 2008.
71. Kronenwett U, Huwendiek Sr, Ostring C, Portwood N, Roblick UJ, Pawitan Y, et al. Improved Grading of Breast Adenocarcinomas Based on Genomic Instability. Cancer Res 2004;64:904-9.
72. Chin S, Teschendorff A, Marioni J, Wang Y, Barbosa-Morais N, Thorne N, et al. High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biol 2007;8:R215.
73. Lingle WL, Barrett SL, Negron VC, D'Assoro AB, Boeneman K, Liu W, et al. Centrosome amplification drives chromosomal instability in breast tumor development. Proc Natl Acad Sci USA 2002;99:1978-83. (Pubitemid 34169000)
74. Greenman CD, Bignell G, Butler A, Edkins S, Hinton J, Beare D, et al. PICNIC: an algorithm to predict absolute allelic copy number variation with microarray cancer data. Biostatistics 2010;11:164-75.
75. Colella S, Yau C, Taylor JM, Mirza G, Butler H, Clouston P, et al. QuantiSNP: an Objective Bayes Hidden-Markov Model to detect and accurately map copy number variation using SNP genotyping data. Nucleic Acids Res 2007;35:2013-25. (Pubitemid 47061667)
76. Sheffer M, Bacolod MD, Zuk O, Giardina SF, Pincas H, Barany F, et al. Association of survival and disease progression with chromosomal instability: A genomic exploration of colorectal cancer. Proc Natl Acad Sci USA 2009;106:7131-6.
77. Habermann JK, Doering J, Hautaniemi S, Roblick UJ, Bundgen NK, Nicorici D, et al. The gene expression signature of genomic instability in breast cancer is an independent predictor of clinical outcome. Int J Cancer 2009;124:1552-64.
78. Cahill DP, Kinzler KW, Vogelstein B, Lengauer C. Genetic instability and darwinian selection in tumours. Trends Cell Biol 1999;9:M57-60.
79. Nicholson JM, Duesberg P. On the karyotypic origin and evolution of cancer cells. Cancer Genet Cytogenet 2009;194:96-110.
80. Chandhok NS, Pellman D. A little CIN may cost a lot: revisiting aneuploidy and cancer. Curr Opin Genet Dev 2009;19:74-81.
81. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998;396:643-9. (Pubitemid 29003936)
82. Lynch M, Bürger R, Butcher D, Gabriel W. The Mutational Meltdown in Asexual Populations. J Heredity 1993;84:339-44. (Pubitemid 23312694)
83. Weaver BAA, Silk AD, Montagna C, Verdier-Pinard P, Cleveland DW. Aneuploidy Acts Both Oncogenically and as a Tumor Suppressor. Cancer Cell 2007;11: 25-36. (Pubitemid 46070223)